[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, V Tzavara, K Dimakou, G Tzatzagou… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
…, P Koufargyris, K Dimakou, S Savvanis, G Tzatzagou… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[PDF][PDF] Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
…, S Ioannou, A Tomelleri, K Dimakou, G Tzatzagou… - Cell Reports …, 2022 - cell.com
Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms,
but many develop severe symptoms associated with an excessive inflammatory response. …
but many develop severe symptoms associated with an excessive inflammatory response. …
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled …
E Papadopoulou, C Loutradis, G Tzatzagou… - Journal of …, 2021 - journals.lww.com
Objectives: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors reduce the incidence of heart
failure and death in patients with type-2 diabetes mellitus. Arterial stiffness is a prominent …
failure and death in patients with type-2 diabetes mellitus. Arterial stiffness is a prominent …
[HTML][HTML] Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the …
…, S Ioannou, L Dagna, K Dimakou, G Tzatzagou… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
Dapagliflozin does not affect short-term blood pressure variability in patients with type 2 diabetes mellitus
…, C Loutradis, G Tzanis, G Tzatzagou… - American Journal of …, 2021 - academic.oup.com
Background Increased blood pressure variability (BPV) is associated with increased
cardiovascular and all-cause mortality in patients with type-2 diabetes mellitus (T2DM). Sodium-…
cardiovascular and all-cause mortality in patients with type-2 diabetes mellitus (T2DM). Sodium-…
[HTML][HTML] Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled …
…, S Ioannou, L Dagna, K Dimakou, G Tzatzagou… - Critical Care, 2024 - Springer
Background Endotype classification may guide immunomodulatory management of patients
with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions …
with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions …
Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled …
…, P Koufargyris, K Dimakou, S Savvanis, G Tzatzagou… - Nature Medicine, 2021 - nature.com
… Glykeria Tzatzagou … Glykeria Tzatzagou … Glykeria Tzatzagou …
[HTML][HTML] Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
…, E Kostis, L Dagna, S Koukidou, G Tzatzagou… - Cytokine, 2023 - Elsevier
Objectives Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR)
predict progression to severe respiratory failure (SRF) or death among patients with …
predict progression to severe respiratory failure (SRF) or death among patients with …
Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor
…, L Dagna, P Koufargyris, K Dimakou, G Tzatzagou… - medRxiv, 2021 - medrxiv.org
Background In a previous open-label trial, early anakinra treatment guided by elevated
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
